Core Viewpoint - China's State Administration for Market Regulation has stated that Nvidia's acquisition of Mellanox Technologies violated anti-monopoly laws and will continue to investigate the matter, increasing pressure on Nvidia amid ongoing trade discussions between Beijing and Washington [1][2]. Group 1: Regulatory Actions - The investigation by China's regulatory body follows a preliminary review of Nvidia's acquisition of Mellanox Technologies, which was approved under the condition that China would continue to receive supplies [2]. - The U.S. has implemented export controls to restrict high-end chip sales to China, complicating Nvidia's operations in the region [2]. Group 2: Market Impact - Nvidia shares, which had risen by 32% year-to-date, experienced a slight decline in premarket trading following the news of the investigation [3].

AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 –––––––––––––––––––– Zhengye Biotechnology Holding Limited As filed with the U.S. Securities and Exchange Commission on June 14, 2024 Registration No. 333-276436 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Cayman Islands 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Exact name of registrant as specified in its charter) ____________________ (Primary Standard In ...